Does TEMSIROLIMUS Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with TEMSIROLIMUS (Temsirolimus). This represents 0.3% of all adverse event reports for TEMSIROLIMUS.
5
Reports of Second primary malignancy with TEMSIROLIMUS
0.3%
of all TEMSIROLIMUS reports
1
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From TEMSIROLIMUS?
Of the 5 reports, 1 (20.0%) resulted in death, 1 (20.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TEMSIROLIMUS. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TEMSIROLIMUS Cause?
Disease progression (158)
Death (136)
Stomatitis (100)
Anaemia (89)
Neoplasm progression (84)
Vomiting (81)
Diarrhoea (79)
Febrile neutropenia (78)
Pneumonia (76)
Off label use (75)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TEMSIROLIMUS Alternatives Have Lower Second primary malignancy Risk?
TEMSIROLIMUS vs TENAMFETAMINE
TEMSIROLIMUS vs TENAPANOR
TEMSIROLIMUS vs TENECTEPLASE
TEMSIROLIMUS vs TENELIGLIPTIN
TEMSIROLIMUS vs TENIPOSIDE